Mian, A. A., Haberbosch, I., Khamaisie, H., Agbarya, A., Pietsch, L., Eshel, E., . . . Mahajna, J. (2021). Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K. Web
Citación estilo ChicagoMian, Afsar Ali, et al. Crizotinib Acts As ABL1 Inhibitor Combining ATP-binding With Allosteric Inhibition and Is Active against Native BCR-ABL1 and Its Resistance and Compound Mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K. 2021.
Cita MLAMian, Afsar Ali, et al. Crizotinib Acts As ABL1 Inhibitor Combining ATP-binding With Allosteric Inhibition and Is Active against Native BCR-ABL1 and Its Resistance and Compound Mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K. 2021.